Superior Survival Associated with Treatment at NCI-designated Cancer Centers

Share this content:

the Cancer Therapy Advisor take:

Patients with adult-onset cancer who were treated at National Cancer Institute-designated comprehensive cancer centers (NCICCCs) demonstrated greater survival compared to patients treated at non-NCICCCs, according to an article published online in the journal Cancer.

Participants in the study included 69,579 patients who were recently diagnosed with adult onset (22-65 years) cancers in Los Angeles from 1998 to 2008.

Results showed patients receiving treatment at non-NCICCC facilities had lower overall survival than those who were treated at NCICCCs.

These differences were still present after adjusting for clinical and sociodemographic factors (hepatobiliary: HR, 1.5; 95% CI: 1.4,1.7; P<0.001; lung: HR, 1.4; 95% CI: 1.3, 1.6; P<0.001; pancreatic: HR, 1.5; 95% CI: 1.3, 1.7; P<0.001; gastric: HR, 1.3; 95% CI: 1.1, 1.7; P =0.01; breast: HR, 1.3; 95% CI: 1.1, 1.5; P<0.001; and colorectal: HR, 1.2; 95% CI: 1.0, 1.4; P =0.05).

Barriers to care at NCICCCs included race/ethnicity (African-American: OR range across diagnoses: 0.4-0.7; P<0.03; Hispanic: OR range, 0.5-0.7; P<0.04); lack of private insurance (public: OR range, 0.6-0.8; P<0.004; uninsured: OR range, 0.1-0.5; P<0.04); socioeconomic status (high-middle: OR range, 0.4-0.7; P<0.02; middle: OR range, 0.3-0.5; P<0.001; and low: OR range, 0.2-0.6; P<0.01), and residing greater than nine miles from the nearest NCICCC (OR range, 0.5-0.7; P<0.02).

Statin use my decrease the likelihood of lung cancer surgery complications.
Patients with adult-onset cancer who were treated at National Cancer Institute-designated comprehensive cancer centers demonstrated greater survival.
Rigorous processes ensure quality of research and clinical care at National Cancer Institute-designated comprehensive cancer centers (NCICCCs). Unmeasurable elements of structure and process of cancer care delivery warrant evaluation. To the authors' knowledge, the impact of NCICCC care on survival and access to NCICCCs for vulnerable subpopulations remain unstudied.
READ FULL ARTICLE From Wiley Online Library

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters